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Introduction
Buruli ulcer disease (BUD) caused by
Mycobacterium ulcerans involves the skin and
soft tissue. If left untreated, extensive
destruction of tissue followed by scarring
and contractures may lead to severe
functional limitations. Following the intro-
duction of standardized antimycobacterial
chemotherapy with rifampicin and strep-
tomycin, recurrence rates of less than 2%
were reported. However, treatment fail-
ures occur and a variety of secondary
lesions necessitating customized clinical
management strategies have been report-
ed. True recurrences by definition occur
more than three months after completion
of antibiotic treatment, are characterised
by the presence of viable bacilli, and
require a second course of antibiotics.
‘‘Non-healers’’ may harbour viable, possi-
bly drug-resistant M. ulcerans strains and
may benefit from surgical intervention.
Early-onset immune-mediated paradoxi-
cal reactions emerging during or shortly
after treatment do not contain viable
bacilli and may heal under conventional
wound care and/or minor surgery; late-
onset secondary lesions presumably attrib-
utable to secondary infection foci may
clear spontaneously through enhanced
immune responses primed by initial treat-
ment. None of the current diagnostic
techniques is applicable to rapidly address
the pivotal question of the presence of
viable bacilli in non-healers and patients
with secondary BUD lesions, and optimal
time points for collection of follow-up
samples have not yet been investigated.
Therefore, to date treatment monitoring is
mainly based on clinical observation [1–
5]. Reverse transcriptase assays targeting
16S rRNA and mRNA were successfully
applied for the rapid detection of viable
mycobacteria in clinical samples from
patients with tuberculosis and leprosy
[6,7]. To employ this technique for
classification of BUD lesions and monitor-
ing of treatment success we developed a M.
ulcerans–specific RNA-based viability assay
combining a 16S rRNA reverse transcrip-
tase real-time PCR (RT-qPCR) to deter-
mine bacterial viability with an IS2404
quantitative real-time PCR (qPCR) for
increased specificity and simultaneous
quantification of bacilli.
Development and Validation
Ethical Approval
The study was approved by the Com-
mittee of Human Research Publication
and Ethics, School of Medical Sciences,
Kwame Nkrumah University of Science
and Technology, Kumasi, Ghana
(CHRPE/28/09). Written informed con-
sent was obtained from all study partici-
pants, or their legal representatives.
Bacterial Strains, DNA Extracts, and
Clinical Samples
Technical validation of the assay was
performed with 29 M. ulcerans strains
originating from Cameroon [8] and
Ghana (Table 1), as well as DNA extracts
from 18 closely related human pathogenic
mycobacterial species and five bacterial
species frequently colonizing human skin
(Table 2).
Clinical validation was conducted on
pre-treatment swab samples in PANTA
(BD, Heidelberg, Germany) from 24
suspected BUD cases from Agogo Presby-
terian Hospital (n=14) and Tepa Govern-
ment Hospital (n=10), Ghana (Protocol
S1). In addition, post-treatment swab
samples from seven IS2404 PCR con-
firmed BUD patients with incomplete
wound healing were collected at week
nine (Figures 1 and 2).
All clinical samples were subjected to
routine diagnostics (microscopy and
IS2404 dry-reagent-based [DRB] PCR)
at the Kumasi Centre for Collaborative
Research (KCCR) [3].
Primers and Probes
Primers and a hydrolysis probe (TibMol-
Biol, Berlin, Germany) for specific amplifi-
cation of M. ulcerans 16S rRNA were
designed using DNAsis Max (MiraiBio,
San Francisco, USA) by alignment of 16S
rRNA gene sequences (GenBank, National
Center for Biotechnology Information
[NCBI]) from closely related mycobacteria
and other bacteria potentially contaminat-
ing the human skin (Table 2).
For simultaneous quantification by
IS2404 qPCR, the primers described by
Fyfe et al. [9] were used in combination
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with a hydrolysis probe (Table 3) that was
re-designed by DNAsis Max for thermo-
dynamic reasons.
Combined RNA/DNA Extraction,
Reverse Transcription, and Real-Time
qPCR
Culture suspensions and swab samples
were stabilized by RNA protect (Qiagen,
Hilden, Germany) and subjected to All-
Prep DNA/RNA extraction kit (Qiagen)
(Protocols S1 and S2).
M. ulcerans whole transcriptome RNA
from cultures and swab samples was
transcribed to cDNA by QuantiTect Re-
verse Transcription Kit (Qiagen) including
genomic DNA (gDNA) wipeout (Protocol
S2). DNA and cDNA were subjected to
IS2404 qPCR and 16S rRNA RT-qPCR,
respectively, with corresponding controls
(Table 4, Protocols S3 and S4).
Intra- and Inter-Assay Variability
Intra- and inter-assay variability was
assessed by testing of each sample in
quadruplicate within one 96-well plate,
repeated on three different days (Table 5).
Sensitivity
The analytical sensitivity was deter-
mined as lower limit of detection (LOD,
lowest template concentration rendering
amplification of 95% of samples) [10] for
Table 1. M. ulcerans cultures subjected to the 16S rRNA RT/IS2404 qPCR assay.
M. ulcerans Strain Source Origina 16S rRNA RT-qPCRb IS2404 qPCRc
IS2404 qPCR – Wipeout
Controld
K4s-C1 DITM Human isolate – Kamerun Positive Positive Negative
K4s-C2 DITM Human isolate – Kamerun Positive Positive Negative
K4s-C3 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C1 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C2 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C1 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C2 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C3 DITM Human isolate – Kamerun Positive Positive Negative
K5d-C4 DITM Human isolate – Kamerun Positive Positive Negative
K5s-C1 DITM Human isolate – Kamerun Positive Positive Negative
K5s-C2 DITM Human isolate – Kamerun Positive Positive Negative
K5s-C3 DITM Human isolate – Kamerun Positive Positive Negative
K5s-C4 DITM Human isolate – Kamerun Positive Positive Negative
K5s-C5 DITM Human isolate – Kamerun Positive Positive Negative
K7b-C1 DITM Human isolate – Kamerun Positive Positive Negative
K7b-C2 DITM Human isolate – Kamerun Positive Positive Negative
K7b-C3 DITM Human isolate – Kamerun Positive Positive Negative
K7b-C4 DITM Human isolate – Kamerun Positive Positive Negative
K7s-C1 DITM Human isolate – Kamerun Positive Positive Negative
K7s-C2 DITM Human isolate – Kamerun Positive Positive Negative
K12S-C1 DITM Human isolate – Kamerun Positive Positive Negative
941328-C1 DITM Human isolate – Ghana Positive Positive Negative
07-C1 DITM Human isolate – Ghana Positive Positive Negative
DS1-C1 DITM Human isolate – Ghana Positive Positive Negative
97680-C1 DITM Human isolate – Ghana Positive Positive Negative
G.A.P.001-C1 KCCR Human isolate – Ghana Positive Positive Negative
G.A.P.033-C1 KCCR Human isolate – Ghana Positive Positive Negative
G.A.P.071-C1 KCCR Human isolate – Ghana Positive Positive Negative
G.A.P.078-C1 KCCR Human isolate – Ghana Positive Positive Negative
Table 1 shows 29 M. ulcerans cultures that were available at the Department of Infectious Diseases and Tropical Medicine (DITM) and the Kumasi Centre for
Collaborative Research (KCCR) for development and technical validation of the 16S rRNA RT/IS2404 qPCR viability assay and the corresponding test results. Sequence
analysis of 16S rRNA genes from the listed strains revealed 100% nucleotide concordance of the corresponding genomic regions amplified by the 16S rRNA RT-qPCR; no
SNPs or mutations were detected, suggesting a high selectivity of the assay. Sequencing primers are described in Table 3 [11].
aM. ulcerans cultures were available from previous studies from Kamerun (n= 21) and Ghana (n= 4) at DITM [8] or were available at KCCR (n= 4) from the present study.
All strains were of human origin (BUD patients) and confirmed by conventional IS2404 PCR and sequencing of rpoB- and rpsL-genes that revealed the M. ulcerans Agy99
wild-type sequences (GenBank accession no. CP000325.1) [11,12].
bResults of the 16S rRNA RT-qPCR of mycobacterial RNA extracts.
cResults of the IS2404 qPCR of mycobacterial DNA extracts.
dResults of the IS2404 qPCR of genomic DNA (gDNA) wipeout controls (see Protocols S2 and S3); a positive result indicates gDNA contamination of RNA extracts
following DNAse digestions, and a negative result indicates RNA extracts free of gDNA.
doi:10.1371/journal.pntd.0001756.t001
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Table 2. Specificity of 16S rRNA and IS2404 qPCR assays.
Bacterial Species Sourcea Originb 16S rRNAd IS2404e
M. abscessus NRZ Human isolatep 2 2
M. africanum NRZ Human isolatep 2 2
M. avium NRZ Human isolatep 2 2
M. bovis NRZ Cattle isolatep 2 2
M. chelonae NRZ Human isolatep 2 2
M. fortuitum NRZ Human isolatec 2 2
M. gordonae NRZ Human isolatec 2 2
M. gordonae DITM Human isolatec 2 2
M. kansasii NRZ Human isolatep 2 2
M. leprae DITM Human isolatep 2 2
M. malmoense NRZ Human isolatec 2 2
M. marinum NRZ Human isolatep + 2
M. microti NRZ Mouse isolatep 2 2
M. scrofulaceum NRZ Human isolatep 2 2
M. smegmatis NRZ Human isolatep 2 2
M. szulgai NRZ Human isolatep 2 2
M. tuberculosis NRZ Human isolatep 2 2
M. ulcerans DITM Human isolatep + +
M. xenopi NRZ Human isolatec 2 2
E. coli MVP Human isolatec 2 2
P. acnes MVP Human isolatep 2 2
Staph. aureus MVP Human isolatec 2 2
Staph. epidermidis MVP Human isolatec 2 2
Str. pyogenes MVP Human isolatep 2 2
Table 2 shows DNA extracts from closely related mycobacterial species and bacteria potentially contaminating the human skin subjected to the combined 16S rRNA RT/
IS2404 qPCR viability assay and the corresponding test results. Mycobacterial species were selected according to their respective genetic contiguousness to M. ulcerans
Agy99 (GenBank accession no. CP000325.1) within the 16S rRNA gene sequences as determined by BLASTN analysis (GenBank, NCBI) [13]. M., Mycobacterium; E.,
Escherichia; P., Propionibacterium; Staph., Staphylococcus; Str., Streptococcus. While in-silico analysis revealed that the combined 16S rRNA RT/IS2404 assay will also
amplify mycolactone-producing mycobacteria (MPM) other than M. ulcerans (e.g., M. pseudoshottsii, M. liflandii, and the environmental M. marinum [GenBank accession
No. NR_042988.1, AY500838.1, and AF456241.1, respectively]), these MPM species were not included in specificity testing.
aDNA extracts that were not available at the DITM were provided by the National Reference Center (NRZ) for Mycobacteria, Borstel, Germany, and the Max von
Pettenkofer-Institute (MVP), Ludwig-Maximilians University, Munich, Germany.
bThe respective primary patient isolates were considered as ppathogenic bacteria or as ccommensals/contaminants of clinical samples.
dResults of the 16S rRNA RT-qPCR of DNA extracts; ‘‘+’’ indicates a positive and ‘‘–’’ a negative test result.
eResults of the IS2404 qPCR of DNA extracts; ‘‘+’’ indicates a positive and ‘‘–’’ a negative test result.
doi:10.1371/journal.pntd.0001756.t002
Figure 1. Enrolment criteria for the pre-treatment study population. Figure 1 describes enrolment criteria for clinically suspected BUD
patients presenting at Agogo Presbyterian Hospital (n= 14) and Tepa Governmental Hospital (n= 10), Ghana, respectively. None of the eligible study
participants was excluded.
doi:10.1371/journal.pntd.0001756.g001
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both qPCR components using 10-fold
serial dilutions of cloned IS2404 templates
(GenExpress, Berlin, Germany) with
known copy numbers (IS2404 qPCR)
and exactly quantified M. ulcerans whole
genome DNA extracts from cultures (16S
rRNA RT-qPCR). The LOD was two
(IS2404) and six templates (16S rRNA
gene), respectively (Figures 3 and 4).
M. ulcerans DNA and rRNA was
detected in all culture extracts. Out of
24 pre-treatment swab samples, 18
(75.0%; 95%-CI: 57.7%–92.3%) had a
positive IS2404 qPCR result, 12 out of
those were also positive in routine DRB
PCR, and rRNA was detected in 15 out
of these 18 samples (83.3%; 95%-CI:
66.1%–100%); quantification of the three
negative samples revealed a bacillary load
below the LOD of the 16S rRNA RT-
qPCR (Table 6).
All seven post-treatment swab samples
were IS2404 qPCR positive and 16S
rRNA negative.
Specificity
Analysis of DNA extracts revealed 100%
specificity for the combined assay. M.
marinum (human isolate) was amplified by
16S rRNA RT-qPCR; however, simulta-
neous IS2404 qPCRwas negative (Table 2).
Bacillary Survival Times
To investigate the effect of sample
transport on bacillary survival, mycobac-
teriological transport media (PANTA and
LTM) [3] were spiked with viable M.
ulcerans and stored at 4uC and 31uC. RNA
was detectable in both media for.4 weeks
(4uC and 31uC).
After heat-inactivation of M. ulcerans–
spiked PANTA-samples, RNA positivity
decreased significantly within 12 h, whereas
DNA was still detectable after seven days.
Future Application
The assay will support clinicians in
classification of secondary lesions and
selection of adequate clinical management
strategies and provides a powerful tool for
clinical research evaluating novel treat-
ment regimens (Box 1).
Through analysis of sequential samples
collected during antimycobacterial treat-
ment, the assay will be employed to
determine the proportional decrease of
bacterial viability over time and to estab-
lish laboratory-based evidence for optimal
time-points to collect follow-up samples for
treatment monitoring.
Whereas the current format of the assay
is restricted to reference laboratories,
Figure 2. Enrolment criteria for the post-treatment study population. Figure 2 describes enrolment criteria for IS2404 PCR confirmed BUD
patients with incomplete wound healing (collection of swab samples feasible) who presented at Agogo Presbyterian Hospital, Ghana (n=7),
following completion of 56 doses of rifampicin and streptomycin administered within eight weeks. None of the eligible study participants was
excluded.
doi:10.1371/journal.pntd.0001756.g002
Table 3. Primers and probes.
Primer/Probea Sequence (59–39) Target Geneb Nucleotide Positionc Amplicon Sized
MU16S TF
MU16S TR
MU16S TP
CGA TCT GCC CTG CAC TTC
CCA CAC CGC AAA AGC TT
6 FAM-CAC AGG ACA TGA ATC CCG TGG TC-BBQe
16S rRNA 4414800–4414817
4414718–4414734
4414740–4414762
100 bp
IS2404 TF
IS2404 TR
IS2404 TP2
AAA GCA CCA CGC AGC ATC T
AGC GAC CCC AGT GGA TTG
6 FAM-CCG TCC AAC GCG ATC GGC A-BBQe
IS2404 96685–96667
96627–96644
96664–96646
59 bp
T13f
T39f
TGC ACA CAG GCC ACA AGG GA
CG AAC GGG TGA GTA ACA CG
16S rRNA 4413906–4413925
4414822–4414840
935 bp
Table 3 indicates primers and probes designed for the 16S rRNA RT-qPCR, the primers described by Fyfe et al., and a re-designed hydrolysis probe used for the
amplification, detection, and quantification of IS2404 [9].
aTF, forward primer; TR, reverse primer; TP2, hydrolysis probe (TibMolBiol, Berlin, Germany).
b16S rRNA, gene for the ribosomal 16S RNA detected as 16S cDNA; IS2404, insertion sequence 2404.
cNucleotide positions are provided for the first (IS2404) or single (16S rRNA) copy of the respective amplicon in M. ulcerans Agy99 (GenBank accession no. CP000325.1)
as determined by BLASTN analysis within GenBank (NCBI) [13].
dbp, base pairs.
e6 FAM, 6-Carboxyfluorescein fluorescent dye; BBQ, BlackBerry Quencher.
fPrimers T13 (forward) and T39 (reverse) were used for the amplification of a 935-bp region of the M. ulcerans 16S rRNA gene, encompassing the region amplified by
qPCR primers MU16S TF and MU16S TR, to generate single copy replicates. Furthermore, these primers were used for sequencing of the M. ulcerans 16S rRNA gene
(Table 1).
doi:10.1371/journal.pntd.0001756.t003
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Table 4. Controls applied in 16S rRNA RT/IS2404 qPCR.
Control Purpose Material
16S rRNA RT-qPCRa IS2404 qPCRb
gDNA wipeout controlc To exclude DNA contamination
of RNA extracts
Aliquot of each RNA extract
following gDNA wipeout before
reverse transcription
NA
Internal positive control To exclude false negative results
due to inhibition
TaqMan exogenous internal
positive control (IPC)d
TaqMan exogenous internal
positive control (IPC)d
Positive run control To ensure adequate performance
of PCR
M. ulcerans cDNAe Cloned IS2404 standard
Negative no template control To exclude contamination during
PCR set up
H2O H2O
Negative extraction control To exclude contamination during
extraction procedure
NA Extract treated in the same
way as samples
Table 4 indicates controls applied in 16S rRNA RT/IS2404 qPCR. NA, not applicable.
a16S rRNA RT PCR, reverse transcriptase real-time PCR targeting the 16S ribosomal RNA of M. ulcerans.
bIS2404 qPCR, quantitative real-time PCR targeting the insertion sequence (IS) 2404 of M. ulcerans.
cgDNA, genomic DNA wipeout was conducted using DNAses provided in the QuantiTect Reverse Transcription Kit (Qiagen).
dTaqMan exogenous internal positive control (Applied Biosystems, Carlsbad, CA).
ecDNA, complementary DNA obtained through reverse transcription of M. ulcerans RNA by QuantiTect Reverse Transcription Kit (Qiagen).
doi:10.1371/journal.pntd.0001756.t004
Table 5. Intra- and inter-assay variability of the 16S rRNA RT/IS2404 qPCR assay.
qPCR
Targeta Standard No. Run No. 1 Run No. 2 Run No. 3 Intra-Assay Variability Inter-Assay Variability
Ct-rangeb CVc Ct-rangeb CVc Ct-rangeb CVc DCt max.d CV max.e Ct-rangef CVg DCt max.h CV max.i
16S rRNA 1
2
3
4
5
0.23
0.09
0.12
0.15
0.07
0.50
0.19
0.18
0.22
0.10
0.12
0.16
0.06
0.17
0.15
0.48
0.30
0.20
0.25
0.20
0.17
0.19
0.20
0.12
0.16
0.42
0.35
0.32
0.22
0.20
0.23 0.49 0.55
0.24
0.31
0.75
0.71
1.33
0.53
0.55
1.15
0.92
0.75 1.33
IS2404 1
2
3
4
5
6
7
0.12
0.18
0.02
0.18
0.31
0.15
0.35
0.53
0.65
0.07
0.39
0.58
0.23
0.48
0.13
0.15
0.23
0.14
0.25
0.31
0.15
0.54
0.48
0.60
0.28
0.42
0.47
0.33
0.10
0.18
0.11
0.10
0.22
0.20
0.08
0.42
0.57
0.28
0.22
0.38
0.32
0.29
0.35 0.65 0.61
0.71
0.80
0.80
0.58
0.31
0.74
2.67
2.35
2.13
1.76
1.09
0.58
1.10
0.80 2.66
Table 5 shows intra- and inter-assay variability of the 16S rRNA RT/IS2404 qPCR assay.
16S rRNA RT-qPCR: 16S rRNA gene standards (935 bp) were generated by conventional PCR according to Talaat et al. [12]. Quantification of PCR products was
conducted by Picogreen fluorometry (Invitrogen) and copy numbers were calculated based on the known mass of one amplicon. Serial standards were prepared from
PCR products in 5 Log dilutions ranging from 3E+6 (standard no. 1) to 3E+2 copies (standard no. 5) of the 16S rRNA amplicon (PCR template: 2 ml) and were subjected
to the 16S rRNA RT-qPCR in quadruplicate on one 96-well plate to assess intra-assay variability. The runs were repeated on three days to determine the inter-assay
variability between runs 1 through 3. The intra- and inter-assay variability of the 16S rRNA RT-qPCR was low with maximum coefficients of variation (CV) of 0.49 (intra-
assay) and 1.33 (inter-assay).
IS2404 qPCR: Cloned IS2404 replicates (1,047 bp, complete sequence; M. ulcerans Agy99) were used as standards. Quantification of IS2404 templates was conducted by
Picogreen fluorometry (Invitrogen) and copy numbers were calculated based on the known mass of one template. Serial standards were prepared in 7 Log dilutions
ranging from 2E+8 to 2E+2 copies of the IS2404 (PCR template: 2 ml) and were subjected to the IS2404 qPCR in quadruplicate on one 96-well plate to assess intra-assay
variability. The runs were repeated on three days to determine the inter-assay variability between runs 1 through 3. The intra- and inter-assay variability of the IS2404
qPCR was low with maximum CV of 0.65 (intra-assay) and 2.66 (inter-assay).
a16S rRNA, target of the 16S rRNA RT-qPCR; IS2404, target of the IS2404 qPCR.
bCt-range, range of Ct-values of samples tested in the same dilution.
cCV, coefficient of variation of copy numbers from samples tested in quadruplicate of the same dilution.
dDCt max., maximum Ct-variation of all samples tested within one run.
eCV max., maximum CV of all samples tested within one run.
fCt-range, range of Ct-values of samples tested in the same dilution within three runs.
gCV of samples in the same dilution tested within three runs.
hDCt max. of all samples tested within three runs.
iCV max. of all samples tested within three runs.
doi:10.1371/journal.pntd.0001756.t005
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Figure 3. Standard curve and limit of detection of the 16S rRNA RT-qPCR. Figure 3 shows Ct-values of clinical samples plotted versus
quantified 16S rRNA copy numbers. Standards for the 16S rRNA RT-qPCR were generated by conventional PCR amplification (Table 5). Log 10 fold
serial dilutions (n= 5) were prepared ranging from 3E+6 to 300 copies of the 16S rRNA gene (PCR template: 2 ml) and were subjected to the assay in
quadruplicate to generate a calibration curve. The regression line was y =23.4x+41.68 with a coefficient of correlation .0.99 and the efficiency was
E = 0.97. M. ulcerans whole genome extracts were quantified by means of IS2404 qPCR and the analytical sensitivity was determined as limit of
detection (LOD) by subjecting 10 aliquots of a dilution series containing 30, 15, 10, 8, 6, 3, or 2 copies of the 16S rRNA gene to the assay. The LOD was
6 copies of the target sequence. The copy number (n= 1) of the 16S rRNA gene per M. ulcerans genome was determined by copy number variation
assay (unpublished data).
doi:10.1371/journal.pntd.0001756.g003
Figure 4. Standard curve and limit of detection of the IS2404 qPCR. Figure 4 shows mean Ct-values of calibration standards and clinical
samples plotted versus the quantified copy number of IS2404. Cloned IS2404 templates were used as standards (Table 5). Log 10 fold serial dilutions
(n=8) were prepared ranging from 2E+8 to 20 copies of the IS2404 (PCR template: 2 ml) and were subjected to the IS2404 qPCR in quadruplicate to
generate a calibration curve. The regression line was y =23.35x+39.10 with a coefficient of correlation .0.99 and the efficiency was E = 0.97. The
analytical sensitivity was determined as limit of detection (LOD) by subjecting 10 aliquots of a dilution series containing 10, 5, 4, 3, 2, or 1 copy of the
IS2404 to the assay. The LOD was 2 copies of the target sequence.
doi:10.1371/journal.pntd.0001756.g004
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Table 6. Study participants, clinical information, and diagnostic results.
Clinical Data Molecular Viability Assaya Routine Diagnosticsb
No.c
BUD
Patientd
Duration
(Weeks)e
Category of
Lesionf IS2404 [Ct]g
Bacillary
Loadh 16S rRNAi MICk PCRl
1 No NA NA Neg [NA] NA Neg 0 Neg
2 Yes 6 III Pos [15,04] .1000 Pos +1 Pos
3 Yes 4 III Pos [26,80] 584 Pos +1 Pos
4 Yes 9 III Pos [32,93] 6–10 Pos 0 Neg
5 Yes 4 I Pos [35,94] 1–5 Neg 0 Neg
6 Yes 8 II Pos [36,72] 1–5 Neg 0 Neg
7 Yes 2 I Pos [36,74] 1–5 Neg 0 Neg
8 Yes 10 I Pos [27,05] 497 Pos +1 Pos
9 No NA NA Neg [NA] NA Neg 0 Neg
10 Yes 3 I Pos [30,61] 42 Pos +1 Pos
11 Yes 8 II Pos [33,89] 6–10 Pos 0 Neg
12 Yes 9 I Pos [33,68] 6–10 Pos 0 Neg
13 Yes 3 III Pos [29,27] 106 Pos +1 Pos
14 Yes 3 I Pos [27,98] 261 Pos +1 Pos
15 Yes 1 I Pos [26,85] 571 Pos +1 Pos
16 Yes 2 I Pos [33,07] 6–10 Pos 0 Pos
17 Yes 2 II Pos [31,44] 24 Pos +1 Pos
18 Yes 3 II Pos [21,85] .1000 Pos +2 Pos
19 Yes 4 III Pos [22,98] .1000 Pos +1 Pos
20 Yes 3 I Pos [23,47] .1000 Pos +2 Pos
21 No NA NA Neg [NA] NA Neg 0 Neg
22 No NA NA Neg [NA] NA Neg 0 Neg
23 No NA NA Neg [NA] NA Neg 0 Neg
24 No NA NA Neg [NA] NA Neg 0 Neg
Table 6 shows suspected BUD cases with ulcerative lesions enrolled in the pre-treatment cohort (Figure 1), clinical information, and diagnostic results. Swab samples
from 24 suspected BUD cases were subjected to 16S rRNA RT/IS2404 qPCR viability assay (swab 1 in PANTA), microscopic examination and enumeration of acid fast
bacilli (AFB) following Ziehl-Neelsen staining (swab 2, direct smear), and conventional IS2404 dry-reagent-based (DRB) PCR (swab 3 in Cell Lysis Solution [Qiagen]). 18
patients were laboratory confirmed by IS2404 qPCR and 15 out of those were RNA positive; the quantification by IS2404 qPCR revealed a bacillary load (1–2 bacilli per
sample) below the lower limit of detection of the RNA assay for samples from three RNA negative patients. All samples from six IS2404 qPCR negative study participants
were also RNA negative. Direct correlation of AFB enumeration with IS2404 qPCR quantification is not feasible due to inhomogeneous distribution of M. ulcerans in
different clinical samples. NA, not applicable; Neg, negative test result; Pos, positive test result.
aResults of the 16S rRNA RT/IS2404 qPCR viability assay. Clinical swab samples in PANTA were directly processed at KCCR, and M. ulcerans DNA and cDNA were
transported to DITM and subjected to qPCR.
bRoutine diagnostics were conducted following standardized procedures at KCCR [3].
cNo., consecutive number of study participants.
dYes, IS2404 qPCR confirmed BUD patients; No, IS2404 negative study participants.
eDuration of disease before presentation of study participants in weeks.
fCategory of lesion according to the World Health Organization’s clinical criteria [1].
gResults of the IS2404 qPCR with corresponding cycle threshold (Ct)-values.
hThe bacillary load in the respective swab samples (No. 2) was estimated on the basis of IS2404 quantification given an IS2404 copy number of 209 copies per M.
ulcerans genome [9]. For bacterial numbers ,10 ranges were estimated.
iResults of the 16S rRNA RT-qPCR.
kMIC, microscopic detection and enumeration of AFB was conducted at KCCR including external quality assurance by DITM. The following scale was applied:
0 = negative, +1 = 10–99 AFB/100 fields, +2 = 1–10 AFB/1 field, +3=more than 10 AFB/1 field.
lPCR, conventional, single target gel-based IS2404 DRB PCR.
doi:10.1371/journal.pntd.0001756.t006
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sample collection on FTA cards in com-
bination with isothermal dry-reagent-based
reverse transcription and amplification for-
mats would facilitate processing of samples
also at a peripheral level and at lower costs.
Conclusions
The novel combined 16S rRNA RT/
IS2404 qPCR assay proved to be highly
sensitive, specific, and efficient in detecting
viable M. ulcerans in clinical samples under
field conditions. The assay is applicable for
classification of secondary lesions and
monitoring of treatment success and pro-
vides a powerful tool for clinical research.
GenBank Accession Numbers
Genes or DNA sequences of mycobac-
terial strains used in this study were
retrieved from GenBank (NCBI) [13].
The respective sequences and accession
numbers are summarized in Table S1.
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Box 1. Advantages and Disadvantages of the Molecular Viability
Assay
Advantages
N Provides a rapid, sensitive, and specific tool to detect viable bacilli in clinical
samples of BUD patients, thus offering an alternative to cultures.
N Supports classification of secondary BUD lesions and monitoring of treatment
success.
Disadvantages
N Current test format requires well equipped laboratory with real-time PCR
facilities.
N Costs per test (approximately 14 J) may limit the applicability.
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